CXCL12 ameliorates neutrophilia and disease severity in SARS-CoV-2 infection

CXCL12 可减轻 SARS-CoV-2 感染引起的嗜中性粒细胞增多症和疾病严重程度

阅读:5
作者:Jian Zheng ,Hima Dhakal ,Enya Qing ,Rejeena Shrestha ,Anne E Geller ,Samantha M Morrissey ,Divyasha Saxena ,Xiaoling Hu ,Hong Li ,Haiyan Li ,Kevin Wilhelmsen ,Linder H Wendt ,Klaus Klumpp ,Patrick S Hume ,William J Janssen ,Rachel Brody ,Kenneth E Palmer ,Silvia M Uriarte ,Patrick Ten Eyck ,David K Meyerholz ,Michael L Merchant ,Kenneth McLeish ,Tom Gallagher ,Jiapeng Huang ,Jun Yan ,Stanley Perlman

Abstract

Neutrophils, particularly low-density neutrophils (LDNs), are believed to contribute to acute COVID-19 severity. Here, we showed that neutrophilia can be detected acutely and even months after SARS-CoV-2 infection in patients and mice, while neutrophil depletion reduced disease severity in mice. A key factor in neutrophilia and severe disease in infected mice was traced to the chemokine CXCL12 secreted by bone marrow cells and unexpectedly, endothelial cells. CXCL12 levels were negatively correlated with LDN numbers in longitudinal analyses of patient blood samples. CXCL12 blockade in SARS-CoV-2-infected mice increased blood/lung neutrophil numbers, thereby accelerating disease progression without changing lung virus titers. The exaggerated mortality caused by CXCL12 blockade could be reversed by neutrophil depletion. In addition, blocking interactions between SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2) reduced CXCL12 levels, suggesting a signal transduction from virus-mediated ACE2 ligation to increased CXCL12 secretion. Collectively, these results demonstrate a previously unappreciated role of CXCL12 in diminishing neutrophilia, including low-density neutrophilia, and its deleterious effects in SARS-CoV-2 infections. The results also support the involvement of SARS-CoV-2-endothelial cell interactions in viral pathogenesis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。